Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A. Vogel Sore Throat lozenges
- Development stage
- Phase 3
- Lead developer
- Bioforce
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
A. Vogel Sore Throat lozenges are a traditional herbal medicinal product containing extracts of *Echinacea purpurea* (Purple Coneflower) and *Salvia officinalis* (Sage). Developed by A. Vogel (Bioforce AG), these lozenges are indicated for the symptomatic relief of acute sore throats (pharyngitis). The *Echinacea* component is standardized for alkylamides, which act as partial agonists at the cannabinoid receptor 2 (CB2), contributing to immunomodulatory and anti-inflammatory effects. The *Salvia officinalis* (Sage) extract provides antiseptic and astringent properties, helping to soothe the inflamed mucous membranes of the throat. The product is widely available as an over-the-counter remedy and has been evaluated in clinical trials for safety and efficacy in treating acute sore throat symptoms.
- Brand names
- A. Vogel Sore Throat lozengesEchinaforce Sore Throat Lozenges
- Other names
- Echinacea and Sage Lozenges
02
Targets
TLR4 (Toll-like receptor 4)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on A. Vogel Sore Throat lozenges.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on A. Vogel Sore Throat lozenges.